港股异动|药品股普涨药明生物升逾4%领涨
格隆汇7月19日丨药品股普涨。药明生物(2269.HK)升逾4%领涨,神威药业涨逾3%,金斯瑞生物科技、中生制药、联邦制药涨逾2%,国药控股、药明康德涨逾1%。
个股方面,中生制药旗下降糖药获药监局批准通过仿制药质量和疗效一致性评价;药明康德荣登2018中国CRO企业20强榜首,本周五连升累涨近15%;联邦制药拟于下周二(23日)派发末期息每股0.0683港元。
板块上,国信证券近日发表研报指,医药板块整体估值处于相对偏低水平,随着政策预期逐渐明朗,板块整体估值有改善空间。中报前瞻表明医药板块业绩增长仍然较为稳健,推荐业绩增长稳健、估值相对合理、预期有修复改善的细分领域龙头。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.